Effect of beta-glucan supplementation on cystic fibrosis colonic microbiota: an in vitro study

BackgroundChildren with cystic fibrosis (CF) present with gut dysbiosis, and current evidence impedes robust recommendations on the use of prebiotics. This study aimed at establishing the prebiotic potential of a commercial beta-glucan on the in vitro colonic microbiota of a child with CF compared to a healthy counterpart (H).MethodsA dynamic simulator of colonic fermentation (twin-SHIME (R) model) was set up including the simulation of the proximal (PC) and distal colon (DC) of the CF and the H subjects by colonizing the bioreactors with faecal microbiota. During two weeks the system was supplied with the beta-glucan. At baseline, during treatment and post-treatment, microbiota composition was profiled by 16 S rRNA and short-chain fatty acids (SCFA) production was determined by GS-MS.ResultsAt baseline, Faecalibacterium, was higher in CF' DC than in the H, along higher Acidaminococcus and less Megasphaera and Sutterella. Beta-glucan supplementation induced increased microbiota richness and diversity in both subjects during the treatment. At genus level, Pseudomonas and Veillonella decreased, while Akkermansia and Faecalibacterium increased significantly in CF.ConclusionThe supplementation with beta-glucan suggests positive results on CF colonic microbiota in the in vitro context, encouraging further research in the in vivo setting.ImpactCurrent evidence supports assessing the effect of prebiotics on modifying cystic fibrosis microbiota.The effect of beta-glucan supplementation was evaluated in a controlled dynamic in vitro colonic ecosystem.Beta-glucan supplement improved diversity in cystic fibrosis colonic microbiota.The treatment showed increased abundance of and in cystic fibrosis.New evidence supports the use of prebiotics in future clinical studies.